Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-12-13

Clinical Trial Update: Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating a booster dose of IMOJEV one year after primary immunization in healthy children in South Korea.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IMOJEV

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Japanese Encephalitis | Phase 3 | Status: COMPLETED | Results posted: 2017-12-13